Fresh off this summer's successful initial public offering and recent international regulatory approvals for its next-generation iStent Inject device, Glaukos Corp. says it is moving aggressively to establish itself as the long-term leader in the nascent micro-invasive glaucoma surgery, or MIGS, market.
The firm raised $113.7 million in its IPO, which closed June 30, and it presented its first post-IPO earnings report on Aug. 12. Glaukos disclosed $17.8 million in net revenue...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?